EBS

#3040
Emergent BioSolutions Inc. Common Stock
8.3 0 USD
-0.12%
Sector: Atención Sanitaria
Básica: USD
Divisa de beneficio: USD
Rango diario
8.26
8.32
Rango anual
7.56
11.46
Cambio diario
-0.12%
Variación mensual
-0.48%
Variación en los últimos 6 meses
-22.57%
Cambio anual
-22.57%
Cierres anteriores
8.3 1
Open
8.2 7
Mínimo
8.2 6
High
8.3 2
Volumen
583
Ver el calendario completo

Financials

Visión general Informes Estadísticas
Trimestre Año
  • Market Capitalization 428.25 M
  • Employee 900
  • Founded 1998
  • CEO Robert G. Kramer Sr. | Joseph C. Papa
  • Website www.emergentbiosolutions.com
  • Headquarter Delaware, United States
  • FIGI BBG000GW06J7
  • Industry Fabricantes de medicamentos — especializados y genéricos
Ingresos totales
Beneficio neto
Beneficio básico por acción
Deuda total
Flujo de caja libre
Efectivo y equivalentes
Ratio precio/beneficio
13.29
Relación precio/flujo de caja
0.94

Emergent BioSolutions Inc. Common Stock

Emergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. It develops vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and it provides medical devices for biodefense purposes. Among the company's products are the controversial BioThrax, the only anthrax vaccine licensed by the U.S. Food and Drug Administration and Narcan for the emergency treatment of opioid overdose. The company also manufactures pharmaceuticals for infectious diseases like cholera and typhoid. During the COVID-19 pandemic, Emergent BioSolutions also produced Johnson & Johnson/Janssen and Oxford–AstraZeneca vaccines at one of its plants; however, this was marked by contamination and other production issues, and millions of doses of vaccine had to be discarded.

Noticias